Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleomycin-induced pneumonitis.

S Sleijfer1

  • 1Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, The Netherlands. sleiffer@hotmail.com

Chest
|August 15, 2001
PubMed
Summary
This summary is machine-generated.

Bleomycin-induced pneumonitis (BIP) causes lung damage through endothelial injury and can lead to fibrosis. Early detection using lung function tests is crucial, though treatments remain limited.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.

Scientific reports·2023
Same author

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.

Breast cancer research and treatment·2023
Same author

Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases.

Clinical & experimental metastasis·2022
Same author

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.

ESMO open·2022
Same author

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.

ESMO open·2021
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
See all related articles

Area of Science:

  • Pulmonology
  • Oncology
  • Toxicology

Background:

  • Bleomycin is a cytotoxic chemotherapy agent known to cause severe pulmonary toxicity.
  • This toxicity, termed bleomycin-induced pneumonitis (BIP), involves lung endothelial damage, cytokine release, and free radical formation.
  • BIP can progress to lung fibrosis and is sometimes fatal.

Purpose of the Study:

  • To review the pathogenesis, risk factors, and detection methods for bleomycin-induced pneumonitis.
  • To highlight the diagnostic challenges and current treatment limitations for BIP.

Main Methods:

  • Review of existing literature on bleomycin-induced pneumonitis.
  • Analysis of diagnostic criteria, including clinical symptoms, radiographic findings, and pulmonary function tests.

Related Experiment Videos

  • Evaluation of the specificity of pulmonary function tests, particularly lung volumes and carbon monoxide transfer capacity.

    • Main Results:

    • Endothelial damage is the central event in BIP pathogenesis, driven by bleomycin-induced cytokines and free radicals.
    • Diagnosis relies on a combination of clinical, radiographic, and pulmonary function data, necessitating exclusion of other conditions.
    • Lung volume assessments are most suitable for detecting BIP, but carbon monoxide transfer capacity may lack specificity in polychemotherapy regimens.

    Conclusions:

    • Bleomycin-induced pneumonitis is a serious, potentially fatal complication of bleomycin chemotherapy.
    • While corticosteroids are commonly used, no definitive effective treatments are established for BIP in humans.
    • Patients who survive BIP typically experience complete recovery with normalization of lung function and imaging abnormalities.